Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Biomarkers of immune checkpoint inhibitor efficacy in cancer.

Literature DB >> 32368180

Biomarkers of immune checkpoint inhibitor efficacy in cancer.

Abstract

Immune checkpoint inhibitor-based therapies that target ctla-4, PD-1, or the PD-1 ligand PD-L1 have received approval in Canada and many parts of the world for the treatment of melanoma, renal cell cancer, urothelial cancer, classical Hodgkin lymphoma, and non-small-cell lung cancer. However only a small proportion of patients derive long-term clinical benefit. Here, we describe the biomarkers associated with the complex relationship between tumour-related immune stimulus, T cell-mediated immune response, and immune modulation of the microenvironment that can help to predict improved patient outcomes. 2020 Multimed Inc.

Entities: Disease Gene Species

Keywords: Immune checkpoints; PD-1; PD-L1; biomarkers; ctla-4

Mesh：

Substances：

Year: 2020 PMID： 32368180 PMCID： PMC7194000 DOI： 10.3747/co.27.5549

Source DB: PubMed Journal: Curr Oncol ISSN： 1198-0052 Impact factor: 3.677

61 in total

Review 1. The blockade of immune checkpoints in cancer immunotherapy.

Authors: Drew M Pardoll
Journal: Nat Rev Cancer Date: 2012-03-22 Impact factor: 60.716

2. PD-L2 is a second ligand for PD-1 and inhibits T cell activation.

Authors: Y Latchman; C R Wood; T Chernova; D Chaudhary; M Borde; I Chernova; Y Iwai; A J Long; J A Brown; R Nunes; E A Greenfield; K Bourque; V A Boussiotis; L L Carter; B M Carreno; N Malenkovich; H Nishimura; T Okazaki; T Honjo; A H Sharpe; G J Freeman
Journal: Nat Immunol Date: 2001-03 Impact factor: 25.606

3. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

Authors: Matthew D Hellmann; Margaret K Callahan; Mark M Awad; Emiliano Calvo; Paolo A Ascierto; Akin Atmaca; Naiyer A Rizvi; Fred R Hirsch; Giovanni Selvaggi; Joseph D Szustakowski; Ariella Sasson; Ryan Golhar; Patrik Vitazka; Han Chang; William J Geese; Scott J Antonia
Journal: Cancer Cell Date: 2018-05-03 Impact factor: 31.743

4. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors: Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal: N Engl J Med Date: 2018-03-21 Impact factor: 91.245

5. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors: Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245

6. Suboptimal Adherence in Clinical Practice to Guidelines Recommendation to Screen for Lynch Syndrome.

Authors: A Jain; L Shafer; H Rothenmund; C A Kim; J Samadder; S Gupta; H Singh
Journal: Dig Dis Sci Date: 2019-06-11 Impact factor: 3.199

7. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

Authors: G J Freeman; A J Long; Y Iwai; K Bourque; T Chernova; H Nishimura; L J Fitz; N Malenkovich; T Okazaki; M C Byrne; H F Horton; L Fouser; L Carter; V Ling; M R Bowman; B M Carreno; M Collins; C R Wood; T Honjo
Journal: J Exp Med Date: 2000-10-02 Impact factor: 14.307

8. Checkpoint molecule PD-1-assisted CD8⁺ T lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.

Authors: Jiaxi Yao; Wei Xi; Yanjun Zhu; Hang Wang; Xiaoyi Hu; Jianming Guo
Journal: Cancer Manag Res Date: 2018-09-11 Impact factor: 3.989

9. Mutational heterogeneity in cancer and the search for new cancer-associated genes.

Authors: Michael S Lawrence; Petar Stojanov; Paz Polak; Gregory V Kryukov; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Chip Stewart; Craig H Mermel; Steven A Roberts; Adam Kiezun; Peter S Hammerman; Aaron McKenna; Yotam Drier; Lihua Zou; Alex H Ramos; Trevor J Pugh; Nicolas Stransky; Elena Helman; Jaegil Kim; Carrie Sougnez; Lauren Ambrogio; Elizabeth Nickerson; Erica Shefler; Maria L Cortés; Daniel Auclair; Gordon Saksena; Douglas Voet; Michael Noble; Daniel DiCara; Pei Lin; Lee Lichtenstein; David I Heiman; Timothy Fennell; Marcin Imielinski; Bryan Hernandez; Eran Hodis; Sylvan Baca; Austin M Dulak; Jens Lohr; Dan-Avi Landau; Catherine J Wu; Jorge Melendez-Zajgla; Alfredo Hidalgo-Miranda; Amnon Koren; Steven A McCarroll; Jaume Mora; Brian Crompton; Robert Onofrio; Melissa Parkin; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Charles W M Roberts; Jaclyn A Biegel; Kimberly Stegmaier; Adam J Bass; Levi A Garraway; Matthew Meyerson; Todd R Golub; Dmitry A Gordenin; Shamil Sunyaev; Eric S Lander; Gad Getz
Journal: Nature Date: 2013-06-16 Impact factor: 49.962

Review 10. Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond.

Authors: Kristina Buder-Bakhaya; Jessica C Hassel
Journal: Front Immunol Date: 2018-06-28 Impact factor: 7.561

9 in total

1. Immunotherapy Benefit in a Patient With Non-Small Cell Lung Cancer and a Rare BRAF Mutation.

Authors: Rebekah Rittberg; Shantanu Banerji; Susan Green; Gefei Qing; David E Dawe
Journal: Cureus Date: 2020-10-28

2. Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy.

Authors: Sven H Loosen; Joao Gorgulho; Markus S Jördens; Maximilian Schulze-Hagen; Fabian Beier; Mihael Vucur; Anne T Schneider; Christiane Koppe; Alexander Mertens; Jakob N Kather; Frank Tacke; Verena Keitel; Tim H Brümmendorf; Christoph Roderburg; Tom Luedde
Journal: Front Oncol Date: 2021-04-01 Impact factor: 6.244

Biomarkers of immune checkpoint inhibitor efficacy in cancer.

Review 1. The blockade of immune checkpoints in cancer immunotherapy.

2. PD-L2 is a second ligand for PD-1 and inhibits T cell activation.

3. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

4. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

5. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

6. Suboptimal Adherence in Clinical Practice to Guidelines Recommendation to Screen for Lynch Syndrome.

7. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

8. Checkpoint molecule PD-1-assisted CD8⁺ T lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.

9. Mutational heterogeneity in cancer and the search for new cancer-associated genes.

Review 10. Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond.

1. Immunotherapy Benefit in a Patient With Non-Small Cell Lung Cancer and a Rare BRAF Mutation.

2. Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy.

3. Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.

Review 4. Advancements of Common Gamma-Chain Family Cytokines in Cancer Immunotherapy.

5. SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer.

Review 6. Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response.

Review 7. Precision medicine: Uses and challenges.

8. Response Prediction in Immune Checkpoint Inhibitor Immunotherapy for Advanced Hepatocellular Carcinoma.

9. Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups.